To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

NCT05405439 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

39

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor voluntarily terminated the study

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: TQB3823 tablets
DRUG: Abiraterone acetate tablets
DRUG: prednisone acetate tablets

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.